Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Zeru Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-7101-2702; OpenAlex author ID A5011680294. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2021: 2 papers · 2022: 5 papers · 2023: 6 papers · 2024: 6 papers · 2025: 5 papers · 2026: 4 papers

Papers 28

  1. Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-026-01251-0↗
  2. IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. Co-author DOI 10.1016/j.gendis.2025.101866↗
  3. Effect of TGFβ-ITGB6 feedback loop on liver metastasis in SMAD4 wild-type pancreatic cancer. Co-author DOI 10.1097/cm9.0000000000003722↗
  4. Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40364-026-00988-y↗
  5. Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. Co-author DOI 10.1007/s10555-025-10297-9↗
  6. Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. Co-author DOI 10.1016/j.canlet.2025.217864↗
  7. Phthalocyanine and photodynamic therapy relieve albumin paclitaxel and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2025.114455↗
  8. EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling. Co-author DOI 10.1186/s12935-025-04000-9↗
  9. Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA. Co-author DOI 10.7150/jca.110659↗
  10. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Co-author DOI 10.1002/jev2.12488↗
  11. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-024-00925-x↗
  12. Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets. Co-author DOI 10.1016/j.bbcan.2024.189183↗
  13. Circulating tumor cells in pancreatic cancer: more than liquid biopsy. Co-author DOI 10.1177/17588359241284935↗
  14. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. Co-author DOI 10.1186/s12935-024-03456-5↗
  15. Construction of a prognostic model with exosome biogenesis- and release-related genes and identification of RAB27B in immune infiltration of pancreatic cancer. Co-author DOI 10.21037/tcr-24-54↗
  16. Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-023-00897-4↗
  17. Prognostic value and immune infiltration of ARMC10 in pancreatic adenocarcinoma via integrated bioinformatics analyses. Co-author DOI 10.1016/j.heliyon.2023.e20464↗
  18. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Co-author DOI 10.1038/s41419-023-05711-5↗
  19. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Co-author DOI 10.1186/s12967-023-04043-4↗
  20. Pancreatic cancer stemness: dynamic status in malignant progression. Co-author DOI 10.1186/s13046-023-02693-2↗
  21. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pgen.1010847↗
  22. Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. Co-author DOI 10.1016/j.heliyon.2022.e10416↗
  23. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Co-author DOI 10.1186/s12935-022-02768-8↗
  24. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Co-author DOI 10.1186/s12935-022-02785-7↗
  25. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs Co-author DOI 10.21203/rs.3.rs-1759071/v2↗
  26. Long Noncoding RNA and Circular RNA: Two Rising Stars in Regulating Epithelial-Mesenchymal Transition of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.910678↗
  27. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs. First author DOI 10.1007/s00018-021-03908-5↗
  28. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-021-00651-8↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bangbo Zhao · 27 shared papers, 2021–2026 · strength 5.86
  2. Weibin Wang · 21 shared papers, 2021–2026 · strength 4.52
  3. Yutong Zhao · 15 shared papers, 2022–2026 · strength 3.43
  4. Yuanyang Wang · 15 shared papers, 2021–2024 · strength 2.70
  5. Cheng Yong Qin · 10 shared papers, 2022–2026 · strength 2.36
  6. Cheng‐Feng Qin · 11 shared papers, 2021–2024 · strength 2.07
  7. Xiaoying Yang · 12 shared papers, 2021–2024 · strength 2.06
  8. Tianyu Li · 8 shared papers, 2024–2026 · strength 1.99
  9. Tianyu Li · 9 shared papers, 2022–2024 · strength 1.73
  10. Cheng Qin · 7 shared papers, 2022–2026 · strength 1.72
  11. Weibin Wang · 7 shared papers, 2023–2026 · strength 1.63
  12. Haoyu Shi · 4 shared papers, 2025–2026 · strength 1.07
  13. Yiping Xie · 4 shared papers, 2025–2026 · strength 1.03
  14. Yutong Zhao · 3 shared papers, 2026 · strength 0.96
  15. Tianhao Li · 5 shared papers, 2021–2024 · strength 0.84
  16. Tianhao Li · 5 shared papers, 2022–2023 · strength 0.83
  17. Xingtong Zhou · 4 shared papers, 2021–2024 · strength 0.71
  18. Haoyu Shi · 1 shared paper, 2026 · strength 0.32
  19. Xiangyu Zhang · 1 shared paper, 2026 · strength 0.29
  20. Yuanyang Wang · 1 shared paper, 2025 · strength 0.27
  21. Lin Chen · 1 shared paper, 2024 · strength 0.23
  22. Yupei Zhao · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.